SynAging announces extension of its collaboration with Europe's largest biopharmaceutical company Download PDF
First Commercial in vitro Test System for Human Neuroprotection in Proteopathic Diseases such as Alzheimer’s and Parkinson’s Download PDF
SynAging Expands its Capabilities: Building a New Animal Facility and Hiring a Head of Pharmacology Download PDF, 150 KB
SynAging is a spin-off from Lorraine University in Nancy, France.
The company was founded in February 2010 by Violette Koziel (President) and Dr. Thierry Pillot (CEO/CSO) and occupies new labs on the university campus.
The company is a service organization (CRO) providing innovative models to investigate neurodegenerative diseases. SynAging’s services have been designed for pharma and biotech companies, as well as the food and nutraceutical industry.
The company has gained a high reputation for time- and cost-effective services by producing highly reproducible data and new insights in the field of proteinopathic neurodegenerative diseases.
SynAging is a revenue funded organization and has no venture captial investors.